Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

被引:61
作者
Mahungu, T. W. [1 ,2 ]
Smith, C. J. [3 ]
Turner, F. [1 ]
Egan, D. [2 ]
Youle, M. [1 ]
Johnson, M. A. [1 ]
Khoo, S. [2 ]
Back, D. J. [2 ]
Owen, A. [2 ]
机构
[1] Royal Free NHS Trust, Dept HIV Med, London NW3 2QG, England
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Sch Biomed Sci, Liverpool L69 3BX, Merseyside, England
[3] Univ Coll Med Sch, Res Dept Infect & Populat Hlth, London, England
关键词
drug disposition; metabolism; pharmacogenetics; pharmacokinetics; INDUCED SKIN RASH; ANTIRETROVIRAL THERAPY; EFAVIRENZ; PHARMACOKINETICS; PHARMACOGENETICS; HIV-1; HEPATOTOXICITY; POLYMORPHISM; ZIDOVUDINE; RESISTANCE;
D O I
10.1111/j.1468-1293.2008.00689.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP-binding cassette sub-family B member 1 (ABCB1) polymorphisms on nevirapine plasma concentrations. A total of 104 patients (82% male; 26% non-Caucasian) were genotyped for eight single nucleotide polymorphisms at four loci (CYP2B6, CYP3A4, CYP3A5 and MDR1). Nevirapine plasma concentrations were determined using high-performance liquid chromatography. Non-Caucasian ethnicity [5609 ng/mL (n=27) for non-Caucasians vs. 3771 ng/mL (n=77) for Caucasians; P < 0.0001] and CYP2B6 516G -> T [GG, 3574 ng/mL (n=50); GT, 4634 ng/mL (n=50); TT, 8170 ng/mL (n=4); P-analysis of variance (anova)=0.001] were significantly associated with a higher nevirapine trough concentration (C-trough). The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P-anova=0.05 and GG, 3645 ng/mL (n=20); GT, 4861 ng/mL (n=17); TT, 9508 ng/mL (n=2); P-anova=0.01, respectively]. In a multivariable analysis, CYP2B6 516G -> T and non-Caucasian ethnicity remained significant predictors of nevirapine C-trough but CYP2B6 516G -> T homozygosity had the greatest effect (108% higher, 46% higher). No associations were found between nevirapine C-trough and the remaining polymorphisms. In this population, both non-Caucasian ethnicity and carriage of the variant allele of CYP2B6 516G -> T were significant predictors of nevirapine C-trough. The association between CYP2B6 516G -> T and higher plasma nevirapine exposure was maintained at both bid and qd dosing.
引用
收藏
页码:310 / 317
页数:8
相关论文
共 37 条
  • [1] Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals
    Almond, LM
    Edirisinghe, D
    Dalton, M
    Bonington, A
    Back, DJ
    Khoo, SH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) : 132 - 142
  • [2] Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
    Colombo, S
    Soranzo, N
    Rotger, M
    Sprenger, R
    Bleiber, G
    Furrer, H
    Buclin, T
    Goldstein, D
    Décosterd, L
    Telenti, A
    [J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) : 599 - 608
  • [3] Incidence and risk factors for nevirapine-associated rash
    de Maat, MMR
    ter Heine, R
    Mulder, JW
    Meenhorst, PL
    Mairuhu, ATA
    van Gorp, ECM
    Huitema, ADR
    Beijnen, JH
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (5-6) : 457 - 462
  • [4] Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals
    de Maat, MMR
    Huitema, ADR
    Mulder, JW
    Meenhorst, PL
    van Gorp, ECM
    Beijnen, JH
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) : 378 - 385
  • [5] Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals
    De Maat, MMR
    Mathôt, RAA
    Veldkamp, AI
    Huitema, ADR
    Mulder, JW
    Meenhorst, PL
    Van Gorp, ECM
    Carlier, H
    Beijnen, JH
    [J]. PHARMACOLOGICAL RESEARCH, 2002, 46 (03) : 295 - 300
  • [6] Nevirapine plasma exposure affects both durability of viral suppression and selection of Nevirapine primary resistance mutations in a clinical setting
    de Requena, DG
    Bonora, S
    Garazzino, S
    Sciandra, M
    D'Avolio, A
    Raiteri, R
    Marrone, R
    Boffito, M
    De Rosa, FG
    Sinicco, A
    Di Perri, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3966 - 3969
  • [7] Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population
    de Vries-Sluijs, TEMS
    Dieleman, JP
    Arts, D
    Huitema, ADR
    Beijnen, JH
    Schutten, M
    van der Ende, ME
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (06) : 599 - 605
  • [8] Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
    Dieterich, DT
    Robinson, PA
    Love, J
    Stern, JO
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S80 - S89
  • [9] Erickson DA, 1999, DRUG METAB DISPOS, V27, P1488
  • [10] Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
    Gatanaga, Hiroyuki
    Hayashida, Tsunefusa
    Tsuchiya, Kiyoto
    Yoshino, Munehiro
    Kuwahara, Takeshi
    Tsukada, Hiroki
    Fujimoto, Katsuya
    Sato, Isao
    Ueda, Mikio
    Horiba, Masahide
    Hamaguchi, Motohiro
    Yamamoto, Masahiro
    Takata, Noboru
    Kimura, Akiro
    Koike, Takao
    Gejyo, Fumitake
    Matsushita, Shuzo
    Shirasaka, Takuma
    Kimura, Satoshi
    Oka, Shinichi
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (09) : 1230 - 1237